Reuters logo
5 个月前
BRIEF-FDA panel votes 18-8 to say benefits of Opana do not outweigh risks
2017年3月14日 / 晚上9点50分 / 5 个月前

BRIEF-FDA panel votes 18-8 to say benefits of Opana do not outweigh risks

March 15 (Reuters) - Endo International Plc

* FDA panel 18-8 to say benefits of reformulated Opana ER do not continue to outweigh its risks; 1 member abstains from voting Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below